View in EDS HTML Full Text PDF Full Text

Naproxen adjunct to fluoxetine for moderate‐to‐severe obsessive‐compulsive disorder: A randomized, double‐blind, placebo‐controlled trial.

Saved in:
Bibliographic Details
Title: Naproxen adjunct to fluoxetine for moderate‐to‐severe obsessive‐compulsive disorder: A randomized, double‐blind, placebo‐controlled trial.
Authors: Shamabadi, Ahmad (AUTHOR), Motavalian, Zahra (AUTHOR), Farahmand, Yalda (AUTHOR), Farahmand, Kimia (AUTHOR), Arabzadeh Bahri, Razman (AUTHOR), Askari, Sanaz (AUTHOR), Ansari, Sahar (AUTHOR), Fallahzadeh, Mohammadali (AUTHOR), Shalbafan, Mohammdreza (AUTHOR), Akhondzadeh, Shahin (AUTHOR)
Source: Psychiatry & Clinical Neurosciences. Dec2024, Vol. 78 Issue 12, p810-817. 8p.
Subjects: Drug side effects, Combination drug therapy, Naproxen, Obsessive-compulsive disorder, Fluoxetine, Clinical trial registries
Abstract: Aim: Current treatments for obsessive‐compulsive disorder (OCD) encounter resistance and limiting adverse events, necessitating novel therapeutic strategies. This study aimed to investigate the benefits of naproxen, a medication with effects on inflammation and neuronal function, on OCD. Methods: One hundred and four OCD outpatients with a Yale‐Brown Obsessive‐Compulsive Scale (Y‐BOCS) score of >21 were equally assigned to receive fluoxetine plus either naproxen 250 mg or matched placebo q12hr. Patients were assessed using the Y‐BOCS by recording the subscale scores at baseline and weeks 5 and 10 to evaluate efficacy. They were also assessed in terms of tolerability. Results: Data from 96 patients were analyzed. The baseline characteristics were comparable between the groups. There were significant time‐treatment interaction effects on the obsession subscale (ηP2 = 0.055) and total (ηP2 = 0.043) scores of Y‐BOCS. Reductions in the obsession subscale and total scores of Y‐BOCS were significantly greater in the fluoxetine plus naproxen group until the endpoint (Cohen's d = 0.560 and Cohen's d = 0.477, respectively). However, the difference in compulsion subscale score changes between the groups was not significant. Respondents with a reduction of ≥35% in Y‐BOCS total scores were significantly more in the fluoxetine plus naproxen group (80.0% versus 47.8%). The side effect frequencies were comparable between the groups. Conclusion: Naproxen, adjunct to fluoxetine, outperformed adjunctive placebo in treating obsession and total symptoms of OCD patients in a safe and tolerable manner. Clinical trial registration: The study protocol was registered and published in the Iranian Registry of Clinical Trials (http://www.irct.ir; registration number IRCT20090117001556N139). [ABSTRACT FROM AUTHOR]
Copyright of Psychiatry & Clinical Neurosciences is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 181276108
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Naproxen adjunct to fluoxetine for moderate‐to‐severe obsessive‐compulsive disorder: A randomized, double‐blind, placebo‐controlled trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Shamabadi%2C+Ahmad%22">Shamabadi, Ahmad</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Motavalian%2C+Zahra%22">Motavalian, Zahra</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Farahmand%2C+Yalda%22">Farahmand, Yalda</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Farahmand%2C+Kimia%22">Farahmand, Kimia</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Arabzadeh+Bahri%2C+Razman%22">Arabzadeh Bahri, Razman</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Askari%2C+Sanaz%22">Askari, Sanaz</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ansari%2C+Sahar%22">Ansari, Sahar</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Fallahzadeh%2C+Mohammadali%22">Fallahzadeh, Mohammadali</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Shalbafan%2C+Mohammdreza%22">Shalbafan, Mohammdreza</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Akhondzadeh%2C+Shahin%22">Akhondzadeh, Shahin</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Psychiatry+%26+Clinical+Neurosciences%22">Psychiatry & Clinical Neurosciences</searchLink>. Dec2024, Vol. 78 Issue 12, p810-817. 8p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Drug+side+effects%22">Drug side effects</searchLink><br /><searchLink fieldCode="DE" term="%22Combination+drug+therapy%22">Combination drug therapy</searchLink><br /><searchLink fieldCode="DE" term="%22Naproxen%22">Naproxen</searchLink><br /><searchLink fieldCode="DE" term="%22Obsessive-compulsive+disorder%22">Obsessive-compulsive disorder</searchLink><br /><searchLink fieldCode="DE" term="%22Fluoxetine%22">Fluoxetine</searchLink><br /><searchLink fieldCode="DE" term="%22Clinical+trial+registries%22">Clinical trial registries</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Aim: Current treatments for obsessive‐compulsive disorder (OCD) encounter resistance and limiting adverse events, necessitating novel therapeutic strategies. This study aimed to investigate the benefits of naproxen, a medication with effects on inflammation and neuronal function, on OCD. Methods: One hundred and four OCD outpatients with a Yale‐Brown Obsessive‐Compulsive Scale (Y‐BOCS) score of >21 were equally assigned to receive fluoxetine plus either naproxen 250 mg or matched placebo q12hr. Patients were assessed using the Y‐BOCS by recording the subscale scores at baseline and weeks 5 and 10 to evaluate efficacy. They were also assessed in terms of tolerability. Results: Data from 96 patients were analyzed. The baseline characteristics were comparable between the groups. There were significant time‐treatment interaction effects on the obsession subscale (ηP2 = 0.055) and total (ηP2 = 0.043) scores of Y‐BOCS. Reductions in the obsession subscale and total scores of Y‐BOCS were significantly greater in the fluoxetine plus naproxen group until the endpoint (Cohen's d = 0.560 and Cohen's d = 0.477, respectively). However, the difference in compulsion subscale score changes between the groups was not significant. Respondents with a reduction of ≥35% in Y‐BOCS total scores were significantly more in the fluoxetine plus naproxen group (80.0% versus 47.8%). The side effect frequencies were comparable between the groups. Conclusion: Naproxen, adjunct to fluoxetine, outperformed adjunctive placebo in treating obsession and total symptoms of OCD patients in a safe and tolerable manner. Clinical trial registration: The study protocol was registered and published in the Iranian Registry of Clinical Trials (http://www.irct.ir; registration number IRCT20090117001556N139). [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Psychiatry & Clinical Neurosciences is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=181276108
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/pcn.13748
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 8
        StartPage: 810
    Subjects:
      – SubjectFull: Drug side effects
        Type: general
      – SubjectFull: Combination drug therapy
        Type: general
      – SubjectFull: Naproxen
        Type: general
      – SubjectFull: Obsessive-compulsive disorder
        Type: general
      – SubjectFull: Fluoxetine
        Type: general
      – SubjectFull: Clinical trial registries
        Type: general
    Titles:
      – TitleFull: Naproxen adjunct to fluoxetine for moderate‐to‐severe obsessive‐compulsive disorder: A randomized, double‐blind, placebo‐controlled trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Shamabadi, Ahmad
      – PersonEntity:
          Name:
            NameFull: Motavalian, Zahra
      – PersonEntity:
          Name:
            NameFull: Farahmand, Yalda
      – PersonEntity:
          Name:
            NameFull: Farahmand, Kimia
      – PersonEntity:
          Name:
            NameFull: Arabzadeh Bahri, Razman
      – PersonEntity:
          Name:
            NameFull: Askari, Sanaz
      – PersonEntity:
          Name:
            NameFull: Ansari, Sahar
      – PersonEntity:
          Name:
            NameFull: Fallahzadeh, Mohammadali
      – PersonEntity:
          Name:
            NameFull: Shalbafan, Mohammdreza
      – PersonEntity:
          Name:
            NameFull: Akhondzadeh, Shahin
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: Dec2024
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-print
              Value: 13231316
          Numbering:
            – Type: volume
              Value: 78
            – Type: issue
              Value: 12
          Titles:
            – TitleFull: Psychiatry & Clinical Neurosciences
              Type: main
ResultId 1